BR0111575A - Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids - Google Patents
Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aidsInfo
- Publication number
- BR0111575A BR0111575A BR0111575-8A BR0111575A BR0111575A BR 0111575 A BR0111575 A BR 0111575A BR 0111575 A BR0111575 A BR 0111575A BR 0111575 A BR0111575 A BR 0111575A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- methods
- aids
- treatment
- monitoring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MEIOS E MéTODOS PARA MONITORAR A TERAPIA ANTI-RETROVIRAL E ORIENTAR AS DECISõES TERAPêUTICAS NO TRATAMENTO DE HIV/AIDS". Esta invenção refere-se a testes de susceptibilidade e resistência de droga antiviral, a serem usados na identificação de regimes de drogas eficazes para o tratamento de infecção do vírus de imunodeficiência humana (HIV) e síndrome de imunodeficiência adquirida (AIDS), e refere-se ainda aos meios e métodos de monitoração da progressão clínica de infecção de HIV e da sua resposta à terapia anti-retroviral, particularmente, terapia inibidora de transcriptase reversa de nucleosídio, usando ensaios de susceptibilidade fenotípicos ou ensaios genotípicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59189400A | 2000-06-12 | 2000-06-12 | |
PCT/US2001/018882 WO2001096611A1 (en) | 2000-06-12 | 2001-06-12 | Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0111575A true BR0111575A (pt) | 2003-06-24 |
Family
ID=24368395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111575-8A BR0111575A (pt) | 2000-06-12 | 2001-06-12 | Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1292712A4 (pt) |
JP (1) | JP2004503253A (pt) |
CN (1) | CN1446265A (pt) |
AU (1) | AU2001266863A1 (pt) |
BR (1) | BR0111575A (pt) |
CA (1) | CA2411401A1 (pt) |
WO (1) | WO2001096611A1 (pt) |
ZA (1) | ZA200210003B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7037644B1 (en) | 1998-05-26 | 2006-05-02 | Virologic, Inc. | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
CN105647947A (zh) * | 2015-12-30 | 2016-06-08 | 南方医科大学 | 一种转移质粒及其构建方法和重组慢病毒 |
CN105648037B (zh) * | 2015-12-30 | 2020-06-05 | 南方医科大学 | 一种重组慢病毒在hiv表型耐药检测中的应用 |
EP4365311A2 (en) * | 2016-09-07 | 2024-05-08 | St Vincent's Hospital Sydney Limited | Methods of detecting lentivirus |
BR112019027993A2 (pt) * | 2017-07-04 | 2020-07-07 | Cavidi Ab | métodos para avaliar a susceptibilidade de um vírus ao tratamento com um fármaco inibidor de uma enzima do vírus do tipo selvagem, para avaliar se um paciente tratado para uma infecção viral tem necessidade de alterar a terapia farmacológica com um fármaco inibidor da enzima viral e para determinar a carga de um vírus em uma amostra do paciente e a dita resistência do vírus ao tratamento com um fármaco inibidor de uma enzima do vírus do tipo selvagem, e, sistema |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5917033A (en) * | 1995-10-31 | 1999-06-29 | University Of Medicine & Dentistry Of New Jersey | Structure based design of inhibitors of HIV-1 reverse transcriptase |
WO1997027332A1 (en) * | 1996-01-26 | 1997-07-31 | Innogenetics N.V. | Method for detection of drug-induced mutations in the reverse transcriptase gene |
ES2177922T3 (es) * | 1996-01-26 | 2002-12-16 | Virco Bvba | Metodo de valoracion la quimioterapia de pacientes hiv-positivos basado en la sensibilidad fenotipica a los farmacos de las cepas de hiv delpaciente. |
CN1204266C (zh) * | 1998-05-26 | 2005-06-01 | 病毒科学公司 | 监控非核苷类逆转录酶抑制剂抗逆转录病毒治疗的途径与方法 |
-
2001
- 2001-06-12 EP EP01944452A patent/EP1292712A4/en not_active Withdrawn
- 2001-06-12 BR BR0111575-8A patent/BR0111575A/pt not_active IP Right Cessation
- 2001-06-12 AU AU2001266863A patent/AU2001266863A1/en not_active Abandoned
- 2001-06-12 CA CA002411401A patent/CA2411401A1/en not_active Abandoned
- 2001-06-12 CN CN01814056A patent/CN1446265A/zh active Pending
- 2001-06-12 WO PCT/US2001/018882 patent/WO2001096611A1/en active Application Filing
- 2001-06-12 JP JP2002510724A patent/JP2004503253A/ja active Pending
-
2002
- 2002-12-10 ZA ZA200210003A patent/ZA200210003B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1292712A1 (en) | 2003-03-19 |
WO2001096611A1 (en) | 2001-12-20 |
EP1292712A4 (en) | 2005-04-20 |
CN1446265A (zh) | 2003-10-01 |
CA2411401A1 (en) | 2001-12-20 |
AU2001266863A1 (en) | 2001-12-24 |
ZA200210003B (en) | 2004-12-22 |
JP2004503253A (ja) | 2004-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9912209A (pt) | Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids | |
BR0011939A (pt) | Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids | |
Imrie et al. | Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine | |
BIGGAR et al. | Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984 | |
BR9911600A (pt) | Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo | |
BR0011555A (pt) | Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga | |
FR16C0028I2 (fr) | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques | |
HUP0101719A2 (hu) | Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával | |
Roca et al. | Hepatitis C virus and human immunodeficiency virus coinfection in Spain | |
WO2002022076A3 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids | |
BR0111575A (pt) | Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids | |
Evon et al. | Fatigue in patients with chronic hepatitis B living in North America: results from the hepatitis B research network (HBRN) | |
WO2002099387A3 (en) | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids | |
KAMANGU et al. | Comparison of an In-House Quantitative Real-Time PCR and COBAS ampliprep/Taqman Roche for determination of viral load for HIV type 1 non-b | |
ATE534729T1 (de) | Hepatitis-b-virus-dna-polymerase und oberflächenantigen-varianten und methoden iher verwendung | |
Duran et al. | Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis | |
ATE449323T1 (de) | Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren | |
WO2002022781A3 (en) | Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy | |
Taylor | Vibration white finger: a newly prescribed disease. | |
MXPA03003476A (es) | Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco. | |
DE60321466D1 (de) | Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase | |
Lee et al. | The use of total lymphocyte count (TLC) as an independent criterion for initiating HAART in resource-poor countries | |
Weiss | HIV infection and the healthcare worker | |
WO2006130449A3 (en) | Method for determining resistance of hiv to nucleoside reverse transcriptase inhibitor treatment | |
Smolen-Dzirba et al. | Transmission of drug-resistant HIV-1 variants among individuals with recent infection in southern Poland |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE 6A., 7A., E 8A. ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009. |